




RealRate

PHARMACEUTICAL 2014

Tenax Therapeutics INC
Rank 217 of 234



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Tenax Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Tenax Therapeutics INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 3.0% points. The greatest weakness of Tenax Therapeutics INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 86% points.

The company's Economic Capital Ratio, given in the ranking table, is 60%, being 183% points below the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	1,842
Cost of Goods Sold	0
Intangible Assets	925
Liabilities, Current	1,910
Liabilities, Non-Current	55
Other Assets	208
Other Compr. Net Income	0
Other Expenses	4,486
Other Liabilities	2,994
Other Net Income	12
Other Revenues	1,191
Property and Equipment	205
Research and Development	2,456
Selling, General and Administrative Expense	3,676

Output Variable	Value in 1000 USD
Assets	3,181
Liabilities	4,959
Expenses	10,618
Revenues	1,191
Stockholders Equity	-1,778
Net Income	-9,416
Comprehensive Net Income	-9,416
BaseVar	9,980
ECR before LimitedLiability	-327%
Economic Capital Ratio	60%